top of page
PLG expands US market
Global leader in end-to-end regulatory compliance services, the ProductLife Group ( is strengthening its biopharma capability with the acquisition of leading US regulatory drug development consultancy DSI.  PLG’s latest acquisition comes just six months after the acquisition of the Vigilance and Medical Information group AxPharma.

PLG is thus rolling out its strategic plan, defined one year ago with the arrival of Xavier Duburcq as CEO, with the ambition of becoming by 2023 the leading global provider of regulatory and compliance services for the life sciences industry.

“I’ve been very impressed by DSI.  Their experts all have decades of practical industry and agencies interaction experience, providing an unparalleled perspective on how to navigate new product development in a complex and evolving regulatory environment and ultimately arrive at market in the most efficient way.  We will leverage this experience to support our clients in their global efforts to accelerate the path to approval and to implement compliant drug development strategies,” comments Xavier Duburcq, PLG CEO.

“Together, PLG and DSI will be able to support clients in all stages of the product lifecycle, from pre-clinical work to post-approval compliance though the review and approval processes and market-entry strategy. This is a very exciting step for us all.”

DSI offers one-stop, full-service Regulatory and CMC consulting to pharmaceutical and biopharmaceutical companies, leveraging multidisciplinary teams composed of close to 50 manufacturing, quality, and regulatory affairs experts.  DSI consultants bring decades of experience to every stage of the regulatory and product development process, from initial selection of development and manufacturing sources, design and evaluation of the investigational manufacturing process through the scale-up for commercialization to and through approval.

“We could not be more pleased to become part of a global leader in the life sciences regulatory and compliance industry,” say Edward Narke and Anthony Durning, co-founders at DSI, and Brian Lihou, newly appointed General Manager of DSI.  “Joining PLG is exciting both, for DSI as a business, as well as for our clients which will now have access to additional specialist expertise and international coverage spanning more than 100 countries.”

The new PLG/DSI alliance will pave the way for further acceleration of the two companies’ growth ambitions by allowing clients to benefit from additional expertise, as well as from PLG’s extensive geographical reach.  This allows PLG to expand even further into North America and reinforces its expertise to support clients in the regulatory development of their innovative therapies.
bottom of page